US stock futures flounder amid tech weakness, Fed caution
Investing.com -- Lexaria Bioscience Corp (NASDAQ:LEXX) stock rose 3.4% after the company announced the completion of a key milestone in its Phase 1b glucagon-like peptide-1 (GLP-1) study in Australia.
The drug delivery platform innovator reported that its Contract Research Organization (CRO) has reached the last patient last visit (LPLV) milestone in the GLP-1-H24-4 study. This marks the conclusion of all patient dosing and clinical testing in the trial, with the company now moving to the sample and data analysis phase.
"We are delighted that this important milestone has been achieved on schedule, concluding all patient dosing and clinical testing in our Study," said John Docherty, Lexaria’s President and CSO. The company remains on track to deliver final reporting by late 2025.
Lexaria previously released partial 8-week interim results from the study, which the company described as positive and aligned with its primary endpoint. These interim results reportedly showed favorable safety and tolerability profiles compared to the Rybelsus® control arm, particularly regarding reduced incidence of gastrointestinal adverse events.
The company noted that it remains blinded to the study data until the database work has been completed. Thousands of samples collected during the study are currently being processed and analyzed by the CRO.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.